ABIOSA PHARMA AS: årsregnskap 2018 vs 2017
Grew 100% on revenue
approved 2019-06-30; registry 2019-07-10; journal 2019 657835
Summary
What changed
Comparing Årsregnskap 2018 with 2017 for ABIOSA PHARMA AS. Revenue 597 NOK → 1 194 NOK (+100.0%). Net result +15.1k NOK → +22.2k NOK. Equity 14.9k NOK → -7 315 NOK.
On the constructive side: revenue rose; net result improved. Pressures included: operating result weakened; equity eroded; cash fell.
Also worth watching: thin equity buffer. All figures are taken from the published annual accounts for ABIOSA PHARMA AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 597 NOK to 1 194 NOK (+100.0% YoY). Calculated
-
↑
Net result improved
Net result +15.1k NOK → +22.2k NOK (net margin 2528.5% → 1861.0%). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -15.1k NOK → -22.2k NOK (op. margin -2530.2% → -1861.4%). Calculated
-
↓
Equity eroded
Book equity 14.9k NOK → -7 315 NOK (equity ratio 100.0% → -80.8%). Calculated
-
↓
Cash fell
Bank deposits 14.9k NOK → 9 048 NOK (-39.3% YoY). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -80.8% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation